In addition to that, when focusing on HR-positive/HER2- breast cancer patients showing HER2-low-positive expression on residual disease, we observed a high proportion of patients being classified as having high-risk features based on the previously validated prognostic scores RPCB and CPS-EG score. This evidence concerns the gene ERBB2 and breast cancer.